CONCLUSIONS: We demonstrated that morphologic characteristics of ccRCC could be recovered in the renal cell carcinoma cell line by increasing clear cytoplasm using adipogenic induction. This activates the AMPK-PGC1a pathway and promotes mitochondria biogenesis with no impact on membrane potential, resulting in mitochondria being observed in a healthy state. Progression of malignant differentiation in renal cell carcinoma resulted in a marked decrease in the number and function of mitochondria. This study is expected to provide valuable clues in characterizing and treating the progression of renal cell carcinoma.
INTRODUCTION AND OBJECTIVES:
When grown under stressed conditions, a subset of neoplastic cells can undergo cell-to-cell trafficking of mitochondria through dynamic structures termed tunneling nanotubes. This horizontal mitochondrial transfer (HMT) is a relatively newly described phenomenon that may contribute to chemotherapeutic resistance in several non-urologic cancers. Since HMT might represent a novel mechanism of acquired chemoresistance in renal cell carcinoma (RCC), we sought to determine if HMT occurs in response to treatment with Sunitinib, a first line chemotherapeutic agent.
METHODS: RCC cell lines (A498 and 786-O) were differentially labeled by lentiviral transduction of cytoplasm-localizing enhanced green fluorescent protein (EGFP) or mitochondria-localizing mCherry. Mitochondrial localization of mCherry (mito-mCherry) was achieved by tagging the fluorescent protein with the cyclooxygenase-8 mitochondria targeting sequence. Differentially labeled RCC cells were cultured at a 1:1 ratio and were treated with sunitinib (0uM, 1.25uM, 2.5um, 5uM, 10uM, and 20uM) for 24 hours. HMT was quantified by flow cytometry and visualized by deconvolution microscopy.
RESULTS: HMT occurred between differentially labeled RCC cells. Co-culture of mito-mCherry A498 cells with EGFP+ A498, 786-O, and ACHN cells demonstrated mitochondrial transfer at all concentrations of sunitinib tested. 2.4% of EGFP+ A498 cells received mCherry+ mitochondria in co-culture at 0uM of sunitinib. Mitochondrial transfer was enhanced by sunitinib treatment at all doses tested (e.g. 4.26% at 10uM sunitinib). This phenomenon was not cell line specific as EGFP labeled 786-O cells also acquired mCherry+ mitochondria (8.3%). Deconvolution microscopy of fixed co-cultured cells demonstrated mCherry+ mitochondria within EGFP+ 786-O cells.
CONCLUSIONS: Here we demonstrate for the first time that sunitinib exposure potentiates cell-to-cell transfer of mitochondria in kidney cancer cell lines. The biologic significance of this process in vivo remains to be determined. Our hypothesis is that HMT may contribute to clinically relevant acquired chemoresistance in RCC and experiments are under way to explore this possibility further. 
MP39-20 ADVANCES IN THE DIAGNOSIS OF HEREDITARY KIDNEY CANCER: INITIAL RESULTS OF A MULTIGENE PANEL TEST
Kevin Nguyen*, Jamil Syed, New Haven, CT; Carin Espenschied, Holly Laduca, Aliso Viejo, CA; Ansh Bhagat, New Haven, CT; Timothy O'Rourke, North Haven, CT; Brian Shuch, New Haven, CT INTRODUCTION AND OBJECTIVES: Multigene panel testing has been recently introduced to evaluate hereditary cancer, however, limited information is available regarding its use in kidney cancer. In this study, we describe the outcomes of the first kidney cancer focused panel test.
METHODS: We retrospectively reviewed test results and clinical data of kidney cancer patients who underwent targeted multigene panel testing of 19 genes associated with hereditary kidney cancer from 2013 to 2016. Age of onset, gender, race/ethnicity, and patient/family cancer history were noted. The frequency of positive, inconclusive, and negative results was evaluated. A logistic regression analysis evaluated predictive factors for a positive test.
RESULTS: Patients undergoing testing (n¼1,239) had a median age of diagnosis of 46 years, which is significantly younger than the U.S. population of kidney cancer (p<0.0001). Overall, 6.1%, 75.3%, and 18.6% of individuals had positive, negative, and inconclusive results, respectively. The most commonly altered genes included FLCN and FH, which were 1.8% and 1.3% of cases respectively. TSC2, MET, and PMS2 had the highest rates of variants of unknown significance (VUS) with 2.7%, 2.2%, and 1.7% of cases respectively. Early age of onset was the only factor found to be predictive of a positive test on multivariate analysis (OR 0.975, 95% p¼0.0052). Furthermore, early age of onset may be the only identifying characteristic of low penetrant syndromes, such as those associated with MITF mutations, which did not have a single definitive histology nor a family history of kidney cancer, but had an early median age of onset of 39.
CONCLUSIONS: Multigene panel tests facilitate the identification of hereditary kidney cancer. This testing modality may be particularly useful when a specific syndrome is not suspected based on clinical/family characteristics. Our results support the use of early age of onset for genetic counseling and/or testing.
